ClinicalTrials.gg
Active, not recruitingNCT05311215RAISEUpdated Sep 6, 2023

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

A Phase 2 interventional study of SL-1002 and Placebo in Spasticity, sponsored by Saol Therapeutics Inc. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Saol Therapeutics Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 165 studies in Muscle Spasticity with a site in United States — 34 open to participants now, 43 under way, none of them phase 3. Muscle Spasticity · United States.

Planned enrollment
62nd of 130
32 · median 31
Started
2022
with 11 others
Phase 2
18 of 165
3 open now
Primary completion
2023-09
later than 0 of 42 live
Registered
121st of 165
by date

Among the 165 studies in Muscle Spasticity with a site in United States, this one is the 62nd largest by planned enrollment of the 130 interventional ones that give a count, is one of 12 that started in 2022, is one of 18 in phase 2, reaches primary completion later than 0 of the 42 other live ones, and was the 121st registered.

Muscle Spasticity

622 studies on the registry are indexed under Muscle Spasticity; 130 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

34 of the 165 studies in Muscle Spasticity with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Muscle Spasticity with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled single ascending dose escalation study intended to assess the safety, pharmacokinetics and efficacy of single treatment of SL-1002 in patients with mild to severe limb spasticity. The study will enroll 4 cohorts of 8 patients per cohort for a total of 32 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio. The study period will be up to 26 weeks inclusive of a screening period of up to 2 weeks.

03

Conditions studied

  • Spasticity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Spasticity based on MAS of greater than or equal to 2 in the specified limbs and muscle groups.
  2. Patients who are diagnosed with spasticity of cerebral or spinal origin that can be treated with chemo denervation of the approved cohort-specific nerves. Prior history of chemo denervation must align with Exclusion #3 and #5 as noted below.
  3. Patients who have had spasticity for greater than 6 months and have not had a significant change in their spasticity during recent evaluations or changes in dosing of spasticity medication in the 2 weeks prior to the Screening visit.
  4. Male or female patients between 18-80 years of age, with a (BMI) of 18.0 to 29.9 kg/m2 and a total body weight of ≥50.0 kg for males and ≥45.5 kg for females.
  5. Female patients who are not pregnant.
  6. Female patients of who are sexually active with a male partner must be willing to use one of the following acceptable methods throughout the study and for 30 days after the last study drug administration:

    1. Intra-uterine contraceptive device placed at least 4 weeks prior to study drug administration;
    2. Male condom with intravaginally applied spermicide starting at least 21 days prior to study drug administration;
    3. Hormonal contraceptives starting at least 4 weeks prior to study drug administration must agree to use the same hormonal contraceptive throughout the study;
    4. Sterile male partner (vasectomized since at least 6 months);
  7. Female patients of non-childbearing potential as defined below:

    1. defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause).
    2. Pre-menopausal females with one of the following:
    3. Documented tubal ligation
    4. Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
    5. Hysterectomy
    6. Documented bilateral oophorectomy.
  8. Patients who are mentally coherent and responsive to communication, instructional command and have the ability to communicate proactively as defined by a (MMSE) score of 18 or greater. Patients can be enrolled into the study with or without the assistance of a caregiver based upon Investigator discretion. Patients who are cognitively compromised will be required to have a legally authorized representative consent for the study on their behalf.
  9. Patients who have a positive response to baseline screening of 2-8mL lidocaine 1% solution administration.
  10. Patients with no prior history or significant trauma to the injected limbs.

Exclusion criteria

Exclusion Criteria:

  1. Muscle contractures of the targeted upper or lower limb joints or any challenge that causes severe restriction of range of motion of targeted joints. Contractures will be identified by the Investigator following the lidocaine block by assessing the response.
  2. Patients with severe muscle atrophy in the targeted limbs.
  3. Patients who have had long-term treatments to block nerves (alcohol, phenol, etc.) that will be targeted in the study within 1 year of the Screening visit.
  4. Patients currently on intrathecal or oral baclofen therapy for spasticity who have not been on a stable dose regimen for at least 2 weeks prior to the Screening Visit or who would need to have significant dose adjustments at any time point during study participation.
  5. Patients who have received any botulinum toxin in the targeted muscle groups for the nerve block treatment within 6 months of the Screening Visit. Note: patients will not be able to receive any botulinum toxin injections to the targeted muscle group from the Screening Visit to the End of Study visit.
  6. Patients with bleeding disorders or who are being treated with anticoagulants.
  7. Patients with severe hepatic or renal impairment that, in the judgement of the Principal Investigator, will preclude participation in the study.
  8. Female patients who are pregnant or planning to become pregnant during the duration of the study.
  9. Female patients who are breast-feeding.
  10. Patients who are unable or unwilling to comply with the requirements of the protocol.
  11. Patients taking any of the following concurrent medications/over-the counter products (refer to Appendix 7 for a list of applicable medications):

    1. Probenecid or other OAT3 inhibitors.
    2. Inhibitors of CYP2E1, such as disulfiram.
  12. Patients with known allergies or to phenol and/or lidocaine and/or their .
  13. Documented history or evidence of alcohol or drug abuse within 1 year of the Screening Visit.
  14. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days of the Screening Visit, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  15. Patients with abnormalities or vital sign abnormalities at the Screening Visit. Patients with ECG or vital sign abnormalities deemed non-clinically significant or unlikely to result in clinical compromise by the Principal Investigator may be considered for study inclusion.
  16. Patients with clinically significant laboratory results at the Screening Visit (as judged by the Principal Investigator).
  17. Any condition, in the opinion of the Principal Investigator, that may pose a significant risk to the patient, confound the results of the study or interfere significantly with the patient's participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    SL-1002

    SL-1002 injectable solution, single dose

    Drug: SL-1002

  • Placebo comparator
    Matching placebo

    Matching placebo injectable solution, single dose

    Drug: Placebo

Interventions

  • SL-1002 injectable solution

  • DrugPlacebo

    Matching placebo injectable solution

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment emergent adverse events (TEAEs) overall

    TEAE timepoints will be observed from the time point of administration of total dose until end of study visit (day 168)

    Time frame: time of study drug administration to end of study visit (day 168)

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Sep 2023, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 5, 2022
StartActual
Apr 22, 2022
Primary completionEst.
Sep 2023
CompletionEst.
Sep 2023
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05311215
Lead sponsor
Saol Therapeutics Inc
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Apr 22, 2022
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Sep 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SL1002

Start the discussion